Any drug that is excluded from Part B rebatable drugs in accordance with 427.101(b) is not subject to inflation-adjusted beneficiary coinsurance
This may result in multiple subgroups under the same group TIN submitting data for the same MVP, which would yield redundant quality measure reporting
Estimated Number of MIPS Eligible Clinicians in the CY 2025 Performance Period/2027 MIPS Payment Year (1) Initial Population of Clinicians Included in the RIA Baseline and Proposed Policies Models For this proposed rule, we applied the same assumptions as in the CY 2024 PFS final rule (88 FR 79505) to estimate our initial population of clinicians based on CY 2022 performance period/2024 MIPS payment year data

Under the proposed revisions, if a beneficiary voluntarily aligns to a Shared Savings Program ACO under 425.402(e), we would not assign the beneficiary to that Shared Savings Program ACO when the beneficiary is also eligible for claims-based assignment to an entity participating in a model tested or expanded under section 1115A of the Act under which claims-based assignment is based solely on (1) claims for primary care and/or other services related to treatment of one or more specific diseases or conditions targeted by the model or (2) claims for services other than primary care service, and for which there has been a determination by the Secretary that waiver of the requirement in section 1899(c)(2)(B) of the Act is necessary for purposes of testing the model
They include: Chewing tobacco is placed in the mouth, cheek, or inner lip